2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) in July. This was the third new approval since 2021. Kisunla, which is ...
But Mr Cummings said they offered evidence of how to target dementia and “this learning is going to open the door to new therapies of many types, and those drugs can be exported around the world”.
(“Alpha”) of the improved new drug ZUNVEYL(benzgalantamine delayed-release tablets)(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s type. The Group is ...
(“Alpha”) of the improved new drug ZUNVEYL(benzgalantamine delayed-release tablets)(“ZUNVEY” or the “Product”) for the treatment of mild-to-moderate dementia of the Alzheimer’s ty ...
At the end of this year, we understand different risk factors for dementia and potential treatments more deeply than ever before. Researchers working on the Lancet Commission study, part-funded by ...
The new Center for Genetics Guided Dementia Discovery ... and will engage in immuno-dementia drug discovery research focusing on neural inflammation and the immune system based on strong human ...